– Q3 total product revenue of $54.1 million, a YoY increase of
107.5%. – Q3 DAXXIFY® revenue of $22.0 million, and first full year
revenue post approval of $71.0 million. – Q3 RHA® Collection
revenue of $32.1 million, a YoY increase of 23.2%. – In August,
DAXXIFY was approved by the FDA for the treatment of cervical
dystonia, representing the company's first approval in the
therapeutics market. – DAXXIFY cervical dystonia PrevU program
remains on track with over 150 patients treated. – Conference call
and webcast today at 4:30 p.m. ET.
Revance Therapeutics, Inc. (RVNC), today reported financial
results for the third quarter ended September 30, 2023 and provided
a corporate update.
Financial Highlights
- Total revenue for the three months ended September 30,
2023, nearly doubled to $56.8 million from $29.0 million for the
same period last year, primarily due to the commercialization of
DAXXIFY and sales growth of the RHA Collection of dermal fillers.
Revenue for the third quarter included $32.1 million of RHA
Collection revenue, $22.0 million of DAXXIFY revenue and $2.7
million of service revenue. Revenue for the nine months ended
September 30, 2023 was $164.2 million compared to $82.6 million for
the same period in 2022.
- Selling, general and administrative (SG&A) expenses
for the three and nine months ended September 30, 2023, were $69.1
million and $212.5 million compared to $65.8 million and $158.7
million, respectively, for the same periods in 2022, presented in
accordance with U.S. generally accepted accounting principles
(GAAP). The quarterly increase was primarily due to higher sales
and marketing expenses related to DAXXIFY's launch and the
company's expanded aesthetics field force. Excluding depreciation,
amortization, stock-based compensation, and restructuring charges,
non-GAAP SG&A expenses were $59.1 million and $176.9 million,
respectively, for the three and nine months ended September 30,
2023.
- Research and development (R&D) expenses for the
three and nine months ended September 30, 2023 were $13.1 million
and $59.0 million compared to $26.1 million and $81.7 million,
respectively, for the same periods in 2022. The quarterly decrease
was primarily due to the effects of certain manufacturing-related
expenses capitalized into inventory for DAXXIFY. Excluding
depreciation, amortization, stock-based compensation and
restructuring charges, non-GAAP R&D expenses were $9.9 million
and $46.8 million, respectively, for the three and nine months
ended September 30, 2023.
- Total operating expenses for the three and nine months
ended September 30, 2023 were $196.1 million and $427.1 million
compared to $106.5 million and $280.2 million, respectively, for
the same periods in 2022. Excluding costs of revenue, depreciation,
amortization, stock-based compensation, restructuring and
impairment charges, non-GAAP operating expenses were $69.0 million
and $223.7 million, respectively, for the three and nine months
ended September 30, 2023.
- Net loss for the three and nine months ended September
30, 2023 was $141.2 million and $268.3 million, respectively,
compared to a net loss of $84.7 million and $210.5 million for the
same periods in 2022.
- Restructuring charges related to OPUL® payments
business. In connection with the company’s plan to exit the
OPUL payments business by the end of Q1 2024, the company recorded
restructuring and impairment charges of $95.2 million as of
September 30, 2023, and expects to record up to an additional $3
million in charges through the three months ended March 31,
2024.
- Cash, cash equivalents and short-term investments as of
September 30, 2023 were $300.2 million.
- $50 million second tranche notes issued to Athyrium Capital
in August at an 8.5% fixed interest rate. Revance and Athyrium
Capital amended the company’s existing Note Purchase Agreement,
which was entered into on March 18, 2022. Pursuant to the
amendment, the second tranche commitment was reduced from $100
million to $50 million, and the uncommitted third tranche note was
increased from $100 million to $150 million.
“The third quarter marked an important period for Revance as we
evolved our pricing strategy for DAXXIFY to incorporate real-world
experience and customer feedback gathered during our early roll
out. We are encouraged by the response we've received from our
customers with regards to the price change and believe this
adjustment will help us drive deeper penetration and greater
adoption over time," said Chief Executive Officer Mark J. Foley.
"While early, we are seeing a positive impact on DAXXIFY reorder
rates and purchase volumes and continue to believe that our
innovative and differentiated products will allow us to be a
meaningful player in the facial injectables market."
Foley continued, "We are also excited to have initiated our
cervical dystonia PrevU program which is making great progress and
allowing us to gain important real-world feedback from providers,
patients and payers - all of which will be key to informing our
commercial launch in 2024. Further, with our focus on capital
allocation priorities and our strong cash position, we believe we
have the necessary resources to support the growth of both of our
aesthetics and therapeutics franchises while achieving positive
Adjusted EBITDA in 2025.”
Third Quarter Highlights and Subsequent Updates
- DAXXIFY generated $71.0 million in total sales one year
post-approval, surpassing total first year sales of all Botox®
Cosmetic competitors combined.
- Based on independent survey results, 82% of healthcare
professionals and 84% of patients are satisfied or very satisfied
with the aesthetic results of DAXXIFY. Further, of the attributes
surveyed, DAXXIFY's duration, quick onset, and the improved
appearance of skin quality were cited as the top three reasons
injectors prefer DAXXIFY over their first choice short-acting
toxin1.
- Based on real-world learnings and customer feedback, Revance
introduced new competitive pricing for DAXXIFY on September 1,
2023. The company believes the change will support broad-based
market adoption.
- Q3 DAXXIFY Launch Metrics:
- The number of DAXXIFY vials sold in Q3 increased by 10% from
the prior quarter, with revenue offset by a lower average selling
price (ASP).
- Revenue from reordering accounts and vials sold to reordering
accounts were up 25% and 43%, respectively, from the prior quarter,
with the majority of the increase attributed to the month of
September.
- Revenue from reordering accounts represented approximately
two-thirds of DAXXIFY revenue in the third quarter, the majority of
which was generated in the month of September.
- The company ended the quarter with over 2,500 accounts that
have ordered DAXXIFY.
- The company today appointed Erica Jordan, Senior Vice President
of Commercial to Chief Commercial Officer, Aesthetics. As CCO,
Erica will have global responsibility for all aesthetics commercial
activity including commercial strategy, sales and marketing,
branding, loyalty and engagement.
- In October, DAXXIFY was named to TIME’s Best Inventions of
2023, marking the first time that a facial injectable was selected
to the list. This year, TIME® featured 200 groundbreaking
inventions that have changed the way people live, work, play and
think. The innovations were evaluated based on key factors
including originality, efficacy, ambition and impact. In addition,
DAXXIFY recently won the award for "Longest Lasting Injectable" in
SHAPE's 2023 Beauty Awards.
- During the nine months ended September 30, 2023, the RHA
Collection gained the most market share in the U.S. hyaluronic acid
filler market based on Guidepoint Qsight. Further, in July, the FDA
approved the expansion of RHA 4’s label to include cannula
use.
- Accounts across Revance’s aesthetic portfolio totaled over
6,500 at the end of the third quarter 2023, with over 2,500
accounts ordering DAXXIFY.
- Revance received the FDA's approval for DAXXIFY for the
treatment of cervical dystonia on August 14, 2023. The DAXXIFY
cervical dystonia PrevU program remains on track. Since the
program's initiation on September 1st, over 150 patients have been
treated with DAXXIFY across 17 practices, and the feedback from
physicians, patients and providers have been positive. The company
submitted its J-Code application and expects to receive a permanent
J-Code for DAXXIFY in early 2024, prior to commercial launch
beginning mid-year 2024.
- In September, Revance announced its plans to exit the OPUL
payments business by the end of Q1 2024 to prioritize its capital
allocation. The company expects to generate up to approximately $20
million in annual cost savings, which provides the company
flexibility to reinvest in DAXXIFY aesthetics and therapeutics
commercialization or reduce operating expenses.
- In July, Fosun Pharma’s biologics license application (BLA) for
DAXXIFY for the treatment of cervical dystonia was accepted for
review by China’s National Medical Products Administration (NMPA).
In April, the NMPA accepted Fosun Pharma's BLA for DAXXIFY for the
improvement of glabellar lines. The anticipated approvals for both
indications are expected in 2024.
Financial Outlook
In September 2023, Revance revised its 2023 GAAP and Non-GAAP
operating expense guidance to reflect the company's exit of the
OPUL payments business. Revance expects its 2023 GAAP operating
expenses to be $545 million to $585 million and non-GAAP operating
expenses, which exclude costs of revenue, depreciation and
amortization, stock-based compensation, and restructuring and
impairment charges to be $315 million to $335 million. Revance
expects its 2023 non-GAAP research and development expense to be
$75 million to $85 million. The company’s non-GAAP operating
expense guidance for 2023 primarily reflects increased investments
in its aesthetics commercial infrastructure, including sales team
expansion, and DAXXIFY and RHA Collection commercial
investments.
With current cash, cash equivalents, short-term investments and
anticipated revenues and expenditures, management projects that the
company will be funded to cash flow break-even and expects to reach
positive Adjusted EBITDA in 2025.
Conference Call
Revance will host a corresponding conference call and a live
webcast at 1:30 p.m. PT / 4:30 p.m. ET on November 8, 2023, to
discuss its financial results and provide a corporate update.
Individuals interested in listening to the conference call may do
so by dialing (833) 470-1428 and reference conference ID 509643 or
from the webcast link in the investor relations section of the
company's website at: www.revance.com.
A replay of the call will be available beginning November 8,
2023, at 4:30 p.m. PT / 7:30 p.m. ET to February 8, 2024 at 4:30
p.m. PT / 7:30 p.m. ET. To access the replay, please register
through the webcast link found in the investor relations section of
the company’s website. The webcast will be available in the
investor relations section of company's website for 90 days
following the completion of the call.
1. Independent DAXXIFY survey (N=225), Kx
Advisors, August 2023.
About Revance
Revance is a biotechnology company setting the new standard in
healthcare with innovative aesthetic and therapeutic offerings that
enhance patient outcomes and physician experiences. Revance’s
portfolio includes DAXXIFY (daxibotulinumtoxinA-lanm) for injection
and the RHA Collection of dermal fillers in the U.S. Revance has
also partnered with Viatris Inc. to develop a biosimilar to
onabotulinumtoxinA for injection and Shanghai Fosun Pharmaceutical
to commercialize DAXXIFY in China.
Revance is headquartered in Nashville, Tenn., with additional
office locations in Newark and Irvine, Calif. Learn more at
www.Revance.com, www.RevanceAesthetics.com, www.DAXXIFY.com,
https://hcp.daxxifytherapy.com, or connect with us on LinkedIn.
“Revance”, the Revance logo, and DAXXIFY are registered
trademarks of Revance Therapeutics, Inc. Resilient Hyaluronic Acid®
and RHA are trademarks of TEOXANE SA. BOTOX® is a registered
trademark of Allergan, Inc.
Forward-Looking Statements
Any statements in this press release that are not statements of
historical fact, including statements related to our 2023 financial
outlook, milestone expectations, future expenses, and financial
position; our expected cash flow breakeven; our ability and timing
related to achieving positive adjusted EBITDA; our potential to
drive deeper penetration and greater adoption; including
broad-based market adoption; the impact of our pricing strategy on
volumes sold, account reordering and adoption; our ability to
achieve meaningful share gain; the timing and plans related to the
launch of DAXXIFY for the treatment of cervical dystonia; including
expectations regarding receipt of a J-Code; the exit of the OPUL
payments business and anticipated cost savings generated by the
exit; the growth potential of our products and our business; the
potential to set a new standard of care; the potential benefits of
our products; the extent to which our products are considered
innovative and differentiated; the anticipated approvals of DAXXIFY
and commercialization of DAXXIFY through our Fosun partnership;
development of a biosimilar to onabotulinumtoxinA for injection
with our partner, Viatris; and our business and marketing strategy,
timeline, goals, plans and prospects, including our
commercialization plans; constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995, Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended. You
should not rely upon forward-looking statements as predictions of
future events. Although we believe that the expectations reflected
in the forward-looking statements are reasonable, we cannot
guarantee that the future results, levels of activity, performance,
events, circumstances or achievements reflected in the
forward-looking statements will ever be achieved or occur.
Forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially
from our expectations. These risks and uncertainties relate to, but
are not limited to: our ability to obtain funding for our
operations; the timing of capital expenditures; the accuracy of our
estimates regarding expenses, revenues, capital requirements, our
financial performance and the economics of DAXXIFY and the RHA
Collection of dermal fillers; the extent of future impairment
charges; our ability to comply with our debt obligations; the
impact of macroeconomic factors on our manufacturing operations,
supply chain, end user demand for our products, commercialization
efforts, business operations, regulatory meetings, inspections and
approvals, clinical trials and other aspects of our business and on
the market; our ability to maintain approval of our products; our
ability and the ability of our partners to manufacture supplies for
DAXXIFY and our drug product candidates; our ability to acquire
supplies of the RHA Collection of dermal fillers; the uncertain
clinical development process; our ability to obtain, and the timing
relating to, regulatory submissions and approvals with respect to
our drug product candidates and third-party manufacturers; the risk
that clinical trials may not have an effective design or generate
positive results or that positive results would assure regulatory
approval or commercial success; the applicability of clinical study
results to actual outcomes; the rate and degree of economic
benefit, safety, efficacy, commercial acceptance, market,
competition and/or size and growth potential of DAXXIFY, the RHA
Collection of dermal fillers, and our drug product candidates, if
approved; our ability to successfully commercialize DAXXIFY and to
continue to successfully commercialize the RHA Collection of dermal
fillers; the timing and cost of commercialization activities;
securing or maintaining adequate coverage or reimbursement by
third-party payers for DAXXIFY; the proper training and
administration of our products by physicians and medical staff; our
ability to maintain and gain acceptance from injectors in the use
of DAXXIFY for aesthetic and therapeutic indications; our ability
to expand sales and marketing capabilities; the status of
commercial collaborations; our ability to effectively manage the
exit of the OPUL payments business; changes in and failures to
comply with laws and regulations; our ability to continue obtaining
and maintaining intellectual property protection for our products;
the cost and our ability to defend ourselves in product liability,
intellectual property, class action or other lawsuits; our ability
to limit or mitigate cybersecurity incidents; the volatility of our
stock price; and other risks. Detailed information regarding
factors that may cause actual results to differ materially from the
results expressed or implied by statements in this press release
may be found in our periodic filings with the Securities and
Exchange Commission (SEC), including factors described in the
section entitled "Risk Factors" in our Form 10-K filed with the SEC
on February 28, 2023, and including, without limitation, our Form
10-Qs for the quarters ended March 31, 2023 and June 30, 2023,
filed on May 9, 2023 and August 8, 2023, respectively, and our
Form-10Q for the quarter ended September 30, 2023 expected to be
filed November 8, 2023. The forward-looking statements in this
press release speak only as of the date hereof. We disclaim any
obligation to update these forward-looking statements.
Use of Non-GAAP Financial Measures
Revance has presented certain non-GAAP financial measures in
this release, including non-GAAP SG&A expense, non-GAAP R&D
expense, non-GAAP operating expense and adjusted EBITDA. This
release and the reconciliation tables included herein include
non-GAAP SG&A expense, which excludes depreciation,
amortization, stock-based compensation and restructuring charges;
non-GAAP R&D expense, which excludes depreciation,
amortization, stock-based compensation and restructuring charges;
and total non-GAAP operating expense, which excludes costs of
revenue, depreciation, amortization, stock-based compensation and
restructuring and impairment charges. Adjusted EBITDA is defined as
earnings before interest, taxes, depreciation and amortization,
stock-based compensation and extraordinary items such as
restructuring and impairment charges. Revance excludes costs of
revenue, depreciation, amortization and stock-based compensation
and extraordinary items like restructuring and impairment charges
because management believes the exclusion of these items is helpful
to investors to evaluate Revance's recurring operational
performance. Revance management uses these non-GAAP financial
measures to monitor and evaluate its operating results and trends
on an ongoing basis, and internally for operating, budgeting and
financial planning purposes. The non-GAAP financial measures should
be considered in addition to results prepared in accordance with
GAAP but should not be considered a substitute for or superior to
GAAP results.
Certain non-GAAP measures included in this release were not
reconciled to the comparable GAAP financial measures because the
GAAP measures are not accessible on a forward-looking basis. The
company is unable to reconcile these forward-looking non-GAAP
financial measures to the most directly comparable GAAP measures
without unreasonable effort because the company is currently unable
to predict with a reasonable degree of certainty the type and
extent of certain items that would be expected to impact GAAP
measures for these periods but would not impact the non-GAAP
measures. Such items include costs of revenue, depreciation,
amortization, and stock-based compensation, as well as
extraordinary items like restructuring and impairment charges. The
unavailable information could have a significant impact on the
company’s GAAP financial results.
REVANCE THERAPEUTICS,
INC.
Condensed Consolidated Balance
Sheets
(In thousands, except share
and per share amounts)
(Unaudited)
September 30,
December 31,
2023
2022
ASSETS
CURRENT ASSETS
Cash and cash equivalents
$
179,319
$
108,965
Restricted cash, current
275
—
Short-term investments
120,926
231,742
Accounts receivable, net
25,414
11,339
Inventories
46,214
18,325
Prepaid expenses and other current
assets
16,371
4,356
Total current assets
388,519
374,727
Property and equipment, net
17,179
13,799
Goodwill
—
77,175
Intangible assets, net
10,507
35,344
Operating lease right-of-use assets
54,810
39,223
Finance lease right-of-use asset
23,209
6,393
Restricted cash, non-current
7,145
6,052
Finance lease prepaid expense
30,883
27,500
Other non-current assets
235
1,687
TOTAL ASSETS
$
532,487
$
581,900
LIABILITIES AND STOCKHOLDERS’
EQUITY (DEFICIT)
CURRENT LIABILITIES
Accounts payable
$
4,775
$
4,546
Accruals and other current liabilities
53,493
59,357
Deferred revenue, current
5,371
6,867
Finance lease liability, current
8,610
669
Operating lease liabilities, current
8,659
4,243
Debt, current
1,250
—
Total current liabilities
82,158
75,682
Debt, non-current
427,101
379,374
Deferred revenue, non-current
84,315
78,577
Operating lease liabilities,
non-current
42,279
34,182
Other non-current liabilities
2,835
1,485
TOTAL LIABILITIES
638,688
569,300
STOCKHOLDERS’ EQUITY (DEFICIT)
Preferred stock, par value $0.001 per
share — 5,000,000 shares authorized, and no shares issued and
outstanding as of September 30, 2023 and December 31, 2022
—
—
Common stock, par value $0.001 per share —
190,000,000 shares authorized as of September 30, 2023 and December
31, 2022; 87,813,315 and 82,385,810 shares issued and outstanding
as of September 30, 2023 and December 31, 2022, respectively
88
82
Additional paid-in capital
1,916,385
1,767,266
Accumulated other comprehensive loss
(13
)
(374
)
Accumulated deficit
(2,022,661
)
(1,754,374
)
TOTAL STOCKHOLDERS’ EQUITY (DEFICIT)
(106,201
)
12,600
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY
(DEFICIT)
$
532,487
$
581,900
REVANCE THERAPEUTICS,
INC.
Condensed Consolidated
Statements of Operations and Comprehensive Loss
(In thousands, except share
and per share amounts)
(Unaudited)
Three Months Ended September
30,
Nine Months Ended September
30,
2023
2022
2023
2022
Revenue:
Product revenue
$
54,109
$
26,081
$
154,160
$
72,401
Service revenue
2,664
1,964
9,942
4,046
Collaboration revenue
3
970
139
6,197
Total revenue
56,776
29,015
164,241
82,644
Operating expenses:
Cost of product revenue (exclusive of
depreciation and amortization)
16,821
8,681
46,915
24,130
Cost of service revenue (exclusive of
amortization)
2,592
2,055
9,976
4,022
Selling, general and administrative
69,094
65,775
212,489
158,697
Research and development
13,060
26,103
59,044
81,745
Goodwill impairment
77,175
—
77,175
—
Intangible asset impairment
16,007
—
16,007
—
Depreciation and amortization
1,320
3,885
5,459
11,597
Total operating expenses
196,069
106,499
427,065
280,191
Loss from operations
(139,293
)
(77,484
)
(262,824
)
(197,547
)
Interest income
3,733
1,165
9,851
1,860
Interest expense
(5,093
)
(6,917
)
(13,958
)
(12,722
)
Other expense, net
(223
)
(757
)
(1,056
)
(1,361
)
Loss before income taxes
(140,876
)
(83,993
)
(267,987
)
(209,770
)
Income tax provision
(300
)
(700
)
(300
)
(700
)
Net loss
(141,176
)
(84,693
)
(268,287
)
(210,470
)
Unrealized gain (loss)
48
(74
)
361
(442
)
Comprehensive loss
$
(141,128
)
$
(84,767
)
$
(267,926
)
$
(210,912
)
Basic and diluted net loss
$
(141,176
)
$
(84,693
)
$
(268,287
)
$
(210,470
)
Basic and diluted net loss per share
$
(1.63
)
$
(1.17
)
$
(3.20
)
$
(3.00
)
Basic and diluted weighted-average number
of shares used in computing net loss per share
86,613,425
72,208,285
83,816,577
70,215,148
REVANCE THERAPEUTICS,
INC.
Product Revenue Breakdown
(Unaudited)
Three Months Ended September
30,
Nine Months Ended September
30,
(in thousands)
2023
2022
2023
2022
Product:
RHA® Collection of dermal fillers
$
32,133
$
26,081
$
94,180
$
72,401
DAXXIFY®
21,976
—
59,980
—
Total product revenue
$
54,109
$
26,081
$
154,160
$
72,401
Reconciliation of GAAP
SG&A Expense to Non-GAAP SG&A Expense (Unaudited)
Three Months Ended September
30,
Nine Months Ended September
30,
(in thousands)
2023
2022
2023
2022
GAAP SG&A expense
$
69,094
$
65,775
$
212,489
$
158,697
Adjustments:
Stock-based compensation
(8,599
)
(13,245
)
(31,042
)
(27,937
)
Depreciation and amortization
(633
)
(1,037
)
(3,815
)
(3,189
)
Restructuring charges
(732
)
—
(732
)
—
Non-GAAP SG&A expense
$
59,130
$
51,493
$
176,900
$
127,571
Reconciliation of GAAP R&D
Expense to Non-GAAP R&D Expense (Unaudited)
Three Months Ended September
30,
Nine Months Ended September
30,
(in thousands)
2023
2022
2023
2022
GAAP R&D expense
$
13,060
$
26,103
$
59,044
$
81,745
Adjustments:
Stock-based compensation
(1,688
)
(4,742
)
(7,926
)
(13,676
)
Depreciation and amortization
(172
)
(516
)
(3,000
)
(1,479
)
Restructuring charges
(1,293
)
—
(1,293
)
—
Non-GAAP R&D expense
$
9,907
$
20,845
$
46,825
$
66,590
Reconciliation of GAAP
Operating Expenses to Non-GAAP Operating Expenses
(Unaudited)
Three Months Ended September
30,
Nine Months Ended September
30,
(in thousands)
2023
2022
2023
2022
GAAP operating expenses
$
196,069
$
106,499
$
427,065
$
280,191
Adjustments:
Goodwill and intangible asset
impairment
(93,182
)
—
(93,182
)
—
Costs of revenue (exclusive of
depreciation and amortization)
(19,413
)
(10,736
)
(56,891
)
(28,152
)
Stock-based compensation
(10,287
)
(17,987
)
(38,968
)
(41,613
)
Depreciation and amortization
(2,125
)
(5,439
)
(12,274
)
(16,266
)
Restructuring charges
(2,025
)
—
(2,025
)
—
Non-GAAP operating expenses
$
69,037
$
72,337
$
223,725
$
194,160
REVANCE THERAPEUTICS,
INC.
Reconciliation of Net Loss to
Adjusted EBITDA (Unaudited)
Three Months Ended
Nine Months Ended
(in thousands)
September 30, 2023
September 30, 2022
September 30, 2023
September 30, 2022
Net loss
$
(141,176
)
$
(84,693
)
$
(268,287
)
$
(210,470
)
Adjustments:
Goodwill and intangible asset
impairment
93,182
—
93,182
—
Restructuring charges
2,025
—
2,025
—
Stock-based compensation
10,287
17,987
38,968
41,613
Interest income, net
1,360
5,752
4,107
10,862
Income tax provision
300
700
300
700
Depreciation and amortization
2,125
5,439
12,274
16,266
Adjusted EBITDA
$
(31,897
)
$
(54,815
)
$
(117,431
)
$
(141,029
)
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231108710804/en/
Investors
Revance Therapeutics, Inc.: Jessica Serra, 510-279-6886
jessica.serra@revance.com or Gilmartin Group, LLC.: Laurence Watts,
619-916-7620 laurence@gilmartinir.com
Media
Revance Therapeutics, Inc.: Sara Fahy, 949-887-4476
sfahy@revance.com
Revance Therapeutics (NASDAQ:RVNC)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Revance Therapeutics (NASDAQ:RVNC)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024